share_log

MIRA Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

MIRA Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

MIRA Pharmaceuticals | 10-Q:2024財年三季報
美股SEC公告 ·  2024/11/12 21:50

牛牛AI助理已提取核心訊息

MIRA Pharmaceuticals reported financial results for Q3 2024, with a net loss of $5.5 million for the nine months ended September 30, 2024, compared to $6.2 million in the same period of 2023. The company ended the quarter with $4.1 million in cash, down from $4.6 million at the end of 2023. Research and development expenses increased to $2.4 million from $1.2 million year-over-year, primarily due to pre-clinical research projects.The company made significant progress with its drug development programs, including MIRA-55, its novel oral pharmaceutical marijuana molecule being studied for neuropathic pain, anxiety and cognitive decline. In early 2024, MIRA discovered an improved version of its patented molecule during manufacturing scale-up, leading to the filing of a provisional patent for MIRA-55 which showed enhanced potency and potential efficacy...Show More
MIRA Pharmaceuticals reported financial results for Q3 2024, with a net loss of $5.5 million for the nine months ended September 30, 2024, compared to $6.2 million in the same period of 2023. The company ended the quarter with $4.1 million in cash, down from $4.6 million at the end of 2023. Research and development expenses increased to $2.4 million from $1.2 million year-over-year, primarily due to pre-clinical research projects.The company made significant progress with its drug development programs, including MIRA-55, its novel oral pharmaceutical marijuana molecule being studied for neuropathic pain, anxiety and cognitive decline. In early 2024, MIRA discovered an improved version of its patented molecule during manufacturing scale-up, leading to the filing of a provisional patent for MIRA-55 which showed enhanced potency and potential efficacy in pre-clinical analyses.Management expects current cash reserves to fund operations through Q4 2025, supported by an ATM equity program established in August 2024 that allows for up to $75 million in stock sales. The company has already raised $3.1 million through this program by selling 1.48 million shares at an average price of $1.61. However, management noted substantial doubt about the company's ability to continue as a going concern beyond 12 months without additional funding.
MIRA 藥品公司發佈了2024年第三季度的財務結果,截止到2024年9月30日的九個月淨虧損爲550萬,而2023年同一時期爲620萬。公司在本季度末現金餘額爲410萬,低於2023年末的460萬。研究和開發費用同比增加到240萬,去年爲120萬,主要是由於前臨牀研究項目的原因。公司在藥物開發項目上取得了重大進展,包括MIRA-55,這是一種新型口服藥品大麻分子,正在研究其對神經性疼痛、焦慮和認知衰退的治療。在2024年初,MIRA在製造規模擴張過程中發現了其專利分子的改進版本,併爲MIRA-55提交了臨時專利申請,該版本在前臨牀分析中顯示出增強的效力和潛在的療效。管理層預計,當前的現金儲備...展開全部
MIRA 藥品公司發佈了2024年第三季度的財務結果,截止到2024年9月30日的九個月淨虧損爲550萬,而2023年同一時期爲620萬。公司在本季度末現金餘額爲410萬,低於2023年末的460萬。研究和開發費用同比增加到240萬,去年爲120萬,主要是由於前臨牀研究項目的原因。公司在藥物開發項目上取得了重大進展,包括MIRA-55,這是一種新型口服藥品大麻分子,正在研究其對神經性疼痛、焦慮和認知衰退的治療。在2024年初,MIRA在製造規模擴張過程中發現了其專利分子的改進版本,併爲MIRA-55提交了臨時專利申請,該版本在前臨牀分析中顯示出增強的效力和潛在的療效。管理層預計,當前的現金儲備將支持運營到2025年第四季度,此由2024年8月建立的ATm股權計劃支持,該計劃允許最多7500萬的股票銷售。公司已經通過該計劃籌集了310萬,出售了148萬股,平均售價爲1.61。然而,管理層表示,對於公司的持續經營能力在沒有額外資金的情況下超過12個月存在重大疑慮。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 292

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。